Mindera Health, Inc., a San Diego, CA-based company developing and commercializing next-generation medical technology to enable a new era of skin analytics at the molecular level, closed a $14M convertible note financing.
The round was led by Mountain Group Partners and other existing investors in anticipation of a Series B financing in 2025.
Proceeds will support the continued commercialization of Mindera’s lead product, Mind.Px™.
Led by Ron Rocca, CEO, Mindera Health is a company developing and commercializing next-generation medical technology to enable a new era of skin analytics at the molecular level. Using a proprietary dermal biomarker patch, next-generation sequencing, and machine learning, Mindera Health technology generates clinically validated data to reduce healthcare system costs and improve patient outcomes.
Mind.Px™ is the flagship test of Mindera Health, designed to prospectively predict a patient’s response to biologic drug classes prior to therapeutic selection and treatment. It uses a scalable, minimally invasive dermal biomarker patch that captures over 7,000 biomarkers per sample along with data analytics,
Mindera Health is a CLIA- and CAP-certified laboratory and has received ISO 13485:2016 certification.
FinSMEs
01/08/2024